Amcor stock falls after Raymond James reiterates Market Perform rating
Thomas K. Equels, CEO and President of AIM ImmunoTech (OTC:AIMID) Inc. (NYSE:AIM), recently acquired 107 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The company, currently valued at $72 million, maintains a strong balance sheet with more cash than debt and a healthy current ratio of 1.68. The transaction, which took place on June 13, 2025, saw Equels purchase the shares at a price of $7.697 each, amounting to a total value of $823. Following this acquisition, Equels now holds 38,885 shares of AIM ImmunoTech directly. While the stock has declined nearly 40% over the past six months, it has delivered an impressive 65% return over the last year. This purchase reflects Equels’ continued investment in the company, where he serves as both CEO and a director. For comprehensive insider trading analysis and additional insights, check out InvestingPro, which offers 8 more exclusive tips about AIM ImmunoTech.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.